Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

7 recruiting

Enrollment Performance

Analytics

Early Phase 1

7(87.5%)

N/A

1(12.5%)

8Total

Early Phase 1(7)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT06519565Early Phase 1Recruiting

Safety and Efficacy of PRG-1801 in Recurrent/Refractory Primary Immune Thrombocytopenia (ITP)

Role: collaborator

NCT06691685Early Phase 1Recruiting

A Clinical Study to Evaluate the Safety and Efficacy of ESO-T01 in Treating Relapsed/Refractory Multiple Myeloma.

Role: collaborator

NCT06791681Early Phase 1Recruiting

A Study of ESO-T01 in Treating Relapsed/ Refractory Multiple Myeloma

Role: collaborator

NCT06659653Early Phase 1Recruiting

Safety and Efficacy of PRG-2302 for Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia Disease.

Role: collaborator

NCT06497387Early Phase 1Recruiting

Safety and Efficacy of PRG-1801 for Refractory Lupus Nephritis and IgG4-Related Disease

Role: collaborator

NCT06497361Early Phase 1Recruiting

Safety and Efficacy of PRG-2311 for Refractory Lupus Nephritis and IgG4-Related Disease

Role: collaborator

NCT06277427Not ApplicableRecruiting

Refractory ANCA Associated Vasculitis and Lupus Nephritis Treated With BCMA-targeting CAR-T Cells

Role: collaborator

NCT05652530Early Phase 1Unknown

Clinical Study of the Safety and Efficacy of BCMA CAR-NK

Role: lead

All 8 trials loaded